M&As announced YTD in 2024

M&A highlights from previous weeks…👇

YTD Summary:

Number Announced:      31

Q1 2024 # Announced:  18

Q2 2024 # Announced:  13

HI-Bio 

Acquired By: Biogen

Announcement Date: May 22, 2024

Acquisition Price: $1.15B + $650M potential milestone payment

Acquisition Date (Closed): Pending

Lead Asset: Felzartamab 

Lead Asset Stage: Phase 2

Indication: Immune-mediated diseases

Proteologix  

Acquired By: Johnson & Johnson

Announcement Date: May 16, 2024

Acquisition Price: $850M + potential milestone payment

Acquisition Date (Closed): Pending

Lead Asset: PX128 

Lead Asset Stage: Phase 1

Indication: Atopic dermatitis and Asthma

Reneo Pharmaceuticals & OnKure (Merger)  

Announcement Date: May 13, 2024

Merger Date (Closed): Pending

Lead Asset: OKI-219 

Lead Asset Stage: Phase 1

Lead Asset Indication: Solid tumors

---

Get a list of all recently funded companies with deeper info to help your sales/BD activities. Contact us to learn more

Article History:

RF, DV, DG (05/23/24)

This article is not investment or legal advice.